Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.
- 2025 royalty income from DAYBUE up 15% to A$65 million
- Cash and short-term investments rose to A$296 million
- Phase 3 Koala trial for NNZ-2591 underway with patient enrolment progressing
- Acadia launches DAYBUE STIX powder formulation in US, driving growth
- Share buyback paused pending capital management review
Robust Financials Back Neuren’s Growth Ambitions
Neuren Pharmaceuticals (ASX:NEU) closed 2025 with a strong financial footing, reporting royalty income of A$65 million, a 15% increase from the previous year, and a net profit after tax of A$30 million. The company’s cash pile swelled to A$296 million by year-end, up from A$222 million, underpinned by A$125 million in net operating cash flow. This financial strength provides a solid runway to fund Neuren’s development pipeline and explore growth opportunities.
Since DAYBUE® (trofinetide) launched in April 2023, cumulative income from the licensing deal with Acadia Pharmaceuticals has reached A$525 million. Acadia’s US net sales hit US$391 million in 2025, growing 12% year-on-year, with more than 1,000 patients receiving shipments in Q4; the highest quarterly patient count since launch. This momentum extended into 2026, with Q1 net sales up 20% to US$101 million and Neuren’s corresponding royalties rising 23% to US$10.4 million. Acadia reaffirmed its full-year 2026 sales guidance of US$460–490 million, implying Neuren royalties between A$70 million and A$77 million depending on exchange rates. These figures reflect the ongoing commercial success of DAYBUE and its expanding patient base in the US market.
DAYBUE STIX Launch Fuels New Growth Avenues
A significant catalyst for future growth is Acadia’s rollout of DAYBUE STIX, a powder formulation of trofinetide approved by the FDA in December 2025. Initially launched on a limited basis in Q1 2026 targeting Rett syndrome Centres of Excellence, the powder has quickly gained traction, with over 250 prescriptions written and caregiver satisfaction exceeding 80%. Approximately 30% of prescriptions were for new or previously discontinued patients, suggesting the formulation is attracting fresh demand.
The broader US rollout began in April 2026, with penetration rates at Centres of Excellence around 60% and roughly 28% in the wider community. This new formulation addresses prior challenges such as refrigeration requirements and dosage flexibility, potentially expanding the market beyond the current patient base. Early expert consensus has also recommended trofinetide as part of standard care for Rett syndrome, further supporting uptake. The DAYBUE STIX launch builds on the steady sales growth Neuren has enjoyed and could accelerate revenue growth in coming quarters, as noted in the recent DAYBUE STIX powder gains strong caregiver approval and Q1 2026 DAYBUE net sales up 20% coverage.
Progress on NNZ-2591 Phase 3 Trial in Phelan-McDermid Syndrome
Neuren is advancing the Koala Phase 3 clinical trial for NNZ-2591, targeting Phelan-McDermid syndrome (PMS), a rare neurodevelopmental disorder with no approved treatments. This trial is a pivotal step, designed in alignment with the US FDA, aiming to support a New Drug Application upon positive results. As of the announcement, seven trial sites are activated and enrolling patients, with 14 more sites nearing activation. Nine patients have been randomised at the initial sites, with two already completing the trial. Over 80 families have been referred, reflecting strong community engagement and support.
The Koala trial is the first ever Phase 3 study for PMS, presenting both challenges and opportunities as Neuren navigates uncharted regulatory and clinical territory. Success here could unlock significant value and establish the company as a leader in addressing this unmet medical need. The company is also preparing for clinical development in other indications, including Hypoxic Ischemic Encephalopathy (HIE) and Pitt Hopkins syndrome, with regulatory interactions and IND filings planned for 2026 and 2027.
Capital Management Under Review Amid Strong Growth Prospects
Two months prior, Neuren initiated a share buyback program reflecting management’s view that the company’s valuation did not fully capture its asset strength and growth potential. However, the buyback has been paused as Neuren reassesses capital management strategies in light of the evolving landscape, including projected royalty growth, milestone payments, R&D expenditure, and recent changes to Australian tax laws.
Options under consideration include resuming the buyback and introducing franked dividends to shareholders. The company intends to provide clarity on its capital management approach alongside its half-year results in August. This cautious stance underscores Neuren’s commitment to balancing shareholder returns with sustainable investment in its promising development pipeline.
International Regulatory Milestones and Market Expansion
Beyond the US, Neuren’s partner Acadia is actively pursuing regulatory progress in key markets. A small clinical trial in Japan to support marketing authorisation is underway, with topline results expected between September and November 2026. Japan represents a sizable market opportunity, and positive data could unlock new revenue streams. In Europe, a re-examination process for trofinetide’s approval is anticipated to conclude in late June 2026, potentially reversing prior setbacks and enabling access to European patients.
Acadia’s named patient supply programs outside North America are also contributing to revenue growth, broadening the geographic footprint of DAYBUE. These developments complement the strong US performance and the clinical pipeline, positioning Neuren for sustained global expansion.
Bottom Line?
Neuren’s robust cash reserves and expanding DAYBUE royalties provide a strong foundation as the company advances a landmark Phase 3 trial and evaluates capital returns amid evolving market dynamics.
Questions in the middle?
- How will the broader rollout of DAYBUE STIX impact patient uptake and royalty growth in 2026 and beyond?
- What enrolment pace and trial outcomes can be expected from the Koala Phase 3 study given the rarity of Phelan-McDermid syndrome?
- How might recent Australian tax changes influence Neuren’s decision between share buybacks and franked dividends?